Please login to the form below

Not currently logged in
Email:
Password:

Lupin appoints European president

Maurice Chagnaud moves to India-based company from Teva

India-based Lupin has appointed former Teva senior VP Dr Maurice Chagnaud as president of its European business and head of inhalation strategy.

Dr Chagnaud will be based at the company's operations in Schaffhausen, Switzerland, where he will be responsible for Lupin's business strategy in Europe, including Russia and the CIS countries.

He will also be responsible for developing Lupin's core strategy for inhalation across all developed markets.

Prior to joining Lupin, Dr Chagnaud was senior VP, Central and Eastern Europe, at Israel-based Teva. He was with Teva for just under seven years, with other roles include chief commercial officer in Europe and CEO of the company's operations in France.

In addition, Dr Chagnaud's industry experience also includes time as general manager for Merck KGaA'a generics business in Italy.

20th February 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics